Maryland Heights, MO, August 07, 2016 --(PR.com
)-- The global inhalation and nasal spray generic drugs market is estimated to reach USD 32 Billion in 2020, growing at a CAGR of 6.8% from 2016 to 2020 due to lower cost prescription drugs and increase in respiratory diseases, according to a new market research report Inhalation and Nasal Spray Generic Drugs Market – Global Nasal Indications and Therapeutic Drug Classes Analysis and Forecast 2013-2020, published by iHealthcareAnalyst, Inc.
Visit the Inhalation and Nasal Spray Generic Drugs Market – Global Nasal Indications and Therapeutic Drug Classes Analysis and Forecast 2013-2020 report at http://www.ihealthcareanalyst.com/report/inhalation-nasal-spray-generic-drugs-market/
Intranasal medication delivery is important for both specifically developed pharmaceutical drugs designed for intranasal treatment, as well as for investigating off label uses of commonly available generic medications. Nasal sprays for local effect are quite common. Steroids, antiasthma medications such as salbutamol, ipratropium, montelukast and a large number of inhalational anaesthetic agents are being commonly used. The global inhalation and nasal spray generic drugs market report estimates the market size (Revenue USD million - 2013 to 2020) for key market segments based on the indication type (allergic rhinitis, asthma, COPD, etc.), therapeutic drug classes (antihistamines, bronchodilators – albuterol, epinephrine; combination drugs - Azelastine (benzalkonium chloride), Formoterol (budesonide), Salmeterol (fluticasone); Corticosteroids – beclomethasone, budesonide, flunisolide, fluticasone; decongestant sprays – phenylephrine and oxymetazoline hydrochlorides), and forecasts growth trends (CAGR% - 2016 to 2020). It also provides the detailed market landscape and profiles of major competitors in the global market including company overview, financial snapshot, major products and services offered, and recent trends.
The global inhalation and nasal spray generic drugs is segmented as:
1. Indication Type
1.1. Allergic Rhinitis
1.3. Chronic Obstructive Pulmonary Disease (COPD)
1.4. Other Respiratory Disorders
2. Drug Class
2.3. Combination Drugs
2.3.1. Azelastine (Benzalkonium Chloride)
2.3.2. Formoterol (Budesonide)
2.3.3. Salmeterol (Fluticasone)
2.4.5. Others (Ciclesonide, Mometasone)
2.5. Decongestant Sprays
2.5.1. Phenylephrine Hydrochloride
2.5.2. Oxymetazoline Hydrochloride
3. Geography (Region, Country)
3.1. North America (U.S., Canada)
3.2. Latin America (Brazil, Mexico, Rest of LA)
3.3. Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
3.4. Asia Pacific (Japan, China, India, Rest of APAC)
3.5. Rest of the World
4. Company Profiles
4.1. Allergan plc.
4.2. Beximco Pharmaceuticals
4.3. Cipla Ltd.
4.4. Mylan N.V.
4.5. Nephron Pharmaceuticals Corporation
4.6. Ranbaxy Laboratories Ltd.
4.7. Roxane Laboratories, Inc.
4.8. Sandoz International GmbH (Novartis AG)
4.9. Teva Pharmaceutical Industries Ltd.
iHealthcareAnalyst, Inc. is a global health care market research and consulting company providing market analysis, and competitive intelligence services to global clients. The Company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.
iHealthcareAnalyst, Inc. provides industry participants and stakeholders with strategically analyzed, unbiased view of market dynamics and business opportunities within its coverage areas.
2109, Mckelvey Hill Drive,
Maryland Heights, MO 63043